Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

TCT 2023 San Francisco

PARTNER 3, Evolut and more: TAVR takes the spotlight in 4 late-breaking clinical trials at TCT 2023

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.

October 25, 2023
Akhil Narang, MD, director of the echocardiography laboratory at Northwestern Medicine explains the latest trends in structural heart interventional imaging. #ASE #ASE23 #ASE2023 #structuralheart #echofirst

The evolving roles of TEE and ICE in structural heart interventions

Akhil Narang, MD, explained that the two technologies can be used together to deliver high-quality patient care. 

October 23, 2023
Edwards Lifesciences gained European CE mark approval for Evoque transcatheter tricuspid valve replacement (TTVR) system.

Edwards gains CE mark approval for new tricuspid valve replacement device

The approval represents a significant moment in the treatment of structural heart disease. Edwards will share updated data on the device at TCT 2023 in San Francisco.  

October 19, 2023
While a vast majority of heart transplants in the United States are successful, unplanned hospitalizations after the procedures are still incredibly common. Top 10 reasons for readmission after heart transplant.

SAVR associated with ‘excellent’ long-term survival rates, new research confirms

Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.

October 18, 2023
A late-breaking science presentation at the annual TCT interventional cardiology meeting.

Late-breaking clinical trials at TCT 2023

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

October 17, 2023
The central figure from the study "Predictors and Variation in Cardiac Rehabilitation Participation After Transcatheter Aortic Valve Replacement study 2023," showing the wide variation in the percentage of patients who receive post-TAVR rehab among TAVR patients in Michigan.

Less than one-third of TAVR patients enter cardiac rehab

Only about 30% of patients who underwent TAVR in Michigan participated in cardiac rehabilitation within 90 days after discharge.

October 16, 2023
Medtronic's Evolut FX TAVR valve, designed with 3 golden markers that improve alignment.

Medtronic receives CE mark approval for Evolut FX TAVR system

The self-expanding valve, already approved by the FDA, was designed with three gold markers to boost implanter efficiency, an updated catheter tip and a more flexible delivery system.

October 13, 2023
The SavvyWire TAVR guidewire by OpSens / Haemonetics

Haemonetics to acquire medical device company known for its TAVR guidewires for $253M

Haemonetics expects the deal to increase its short- and long-term revenue. The all-cash transaction should close by January 2024.

October 11, 2023

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup